ADCT’s Q4 Cash, ZYNLONTA Catalysts, and a Royalty Backstop: What the 2025 Results Portend for ADCs

Executive snapshot

ADC Therapeutics SA (ADCT) reported fourth-quarter and full-year 2025 results alongside operational updates. The key takeaways are a modest improvement in net product revenue, a disciplined spend profile as the company winds down discontinued programs, and a heavy emphasis on upcoming LOTIS trials that could redefine the commercial value of ZYNLONTA in 2L+ DLBCL and related indications. The company’s current cash and equivalents of about $261.3 million as of December 31, 2025 provide a runway at least into 2028, a comforting line for a development-stage business navigating multi-tranche trial data and potential regulatory milestones.

Financial highlights at a glance

• Net product revenue for Q4 2025: approximately $22.3 million; full-year 2025 revenue around $73.6 million. These figures sit in the context of prior-year levels and reflect the variability in ordering patterns even as underlying demand remains broadly stable.
• R&D expense for Q4 2025: about $18.2 million; full-year 2025 R&D roughly $104.0 million. The year-over-year decline in quarterly R&D is tied to winding down discontinued programs and IND-enabling work on non-core assets, offset by ongoing ZYNLONTA trials and IND-enabling activity for a PSMA-targeting ADC.
• S&M expense around $12.0 million in Q4 2025, with the full-year figure around $43.4 million.
• Cash position and equivalents stood at $261.3 million as of December 31, 2025, supporting an expected cash runway into 2028.
• Strategic financing activity includes an amendment to HealthCare Royalty financing, providing enhanced strategic flexibility amid ongoing programmatic milestones.

Operational updates and near-term catalysts

The company continues to push LOTIS-5, its Phase 3 confirmatory trial of ZYNLONTA in combination with rituximab for 2L+ DLBCL. Topline results are anticipated in 2Q 2026, with full LOTIS-5 data and LOTIS-7 data in 2L+ DLBCL anticipated by year-end 2026. If data are favorable, the plan includes a supplemental Biologics License Application (sBLA) submission to the FDA, potential compendia inclusions in 2027, and a confirmatory- or regulatory-approval pathway for LOTIS-5 in mid- to late-2027. The scale of the opportunity hinges on durable response rates and safety signals in the combination regimen.

LOTIS-7 remains in ongoing development, with data anticipated by year-end 2026. December 2025 updates from LOTIS-7 suggested strong early efficacy signals in combination with the bispecific antibody glofitamab (COLUMVI) in r/r DLBCL, setting a potentially meaningful data tailwind for ZYNLONTA in combination regimens.

Beyond LOTIS, the company notes ongoing investigator-initiated trials (IITs) evaluating ZYNLONTA in additional B-cell malignancies. Publication timelines target end of 2026 to mid-2027 for UM Sylvester-led trials in follicular lymphoma (r/r FL) and marginal zone lymphoma (MZL), with potential regulatory and compendia pathways contingent on positive data.

Financing structure and strategic flexibility

A notable element of the company’s 2025 narrative is the amendment to the HealthCare Royalty financing agreement. This instrument, effectively a financing backstop tied to future product sales, offers cash-flow flexibility that can support ongoing clinical development and commercial expansion while preserving near-term liquidity. In the context of biotech finance, such arrangements can alter the earnings narrative by shifting some future revenue volatility into a defined royalty stream, which matters for EPS considerations and EPS consensus among equity analysts. The flexibility could help management prioritize R&D and pivotal trials without forcing a near-term accelerant in selling, general, and administrative activity purely to hit an implied earnings target.

What this could portend for ADCT and peers

ADCT’s 2025 results underscore a company in transition: revenue is growing from a narrow base, cash burn remains a reality, and the real equity story hinges on successful LOTIS data readouts and the regulatory path ahead. For ADCT investors, the narrative now folds into a classic biotech hinge: can LOTIS deliver durable clinical benefits that translate into an approved, commercial product and a sustainable revenue stream? The answer will be watched alongside peers pursuing ADC platforms or hematologic-oncology franchises with similar dependency on late-stage trial outcomes and regulatory milestones.

From a sector perspective, the emphasis on partnerships, strategic financing, and a robust data cadence is a recurring theme. The reliance on a few pivotal data releases—LOTIS-5 topline in 2026, LOTIS-5/LOTIS-7 full data by year-end 2026—means the stock may exhibit pronounced sensitivity to Phase 3 narratives and FDA feedback, rather than steady-state quarterly operating metrics. In other words, the earnings landscape for ADCT and its ADC-sector peers remains highly data-driven, with big value creation riding on a handful of data disclosures and regulatory decisions rather than incremental quarterly revenue deltas.

Bottom line

ADCT delivered a financially cautious, data-forward update: modest Q4 revenue gains, disciplined cost management, and a clear line of sight to several high-impact catalysts. The company’s TAM in ZYNLONTA and related regimens will, in the near term, hinge on LOTIS-5 and LOTIS-7 outcomes and FDA/regulatory navigation, all under a financing framework designed to cushion the burn while trials mature. For investors tracking EPS and revenue forecast across the space, ADCT is a reminder that in biotech, the earnings surprise will be less about immediate profit and more about whether a handful of trials can convert into a durable commercial franchise.